This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| James J. Collins | |
|---|---|
| Name | James J. Collins |
| Birth date | 1954 |
| Birth place | Boston, Massachusetts |
| Occupation | Synthetic biologist, bioengineer, entrepreneur, professor |
| Alma mater | Northeastern University, Boston University, Massachusetts Institute of Technology |
| Employer | Massachusetts Institute of Technology, Boston University |
| Known for | Synthetic biology, antibiotic persistence, engineered gene networks, biosensors |
James J. Collins James J. Collins is an American synthetic biologist and bioengineer known for pioneering work on genetic networks, antibiotic persistence, and engineered living therapeutics. He has held faculty positions at Boston University and the Massachusetts Institute of Technology and cofounded multiple biotechnology companies. His research bridges molecular biology, systems biology, and translational applications in diagnostics and therapeutics.
Born in Boston, Massachusetts, Collins attended Xaverian Brothers High School and pursued undergraduate studies at Northeastern University before earning a doctorate at Boston University. He completed postdoctoral training at the Massachusetts Institute of Technology under mentors with connections to Harvard University and the Whitehead Institute. His early influences included work emanating from laboratories associated with Warren Weaver, Sydney Brenner, and contemporaries at Cold Spring Harbor Laboratory.
Collins began his independent career at Boston University where he established a laboratory that integrated concepts from Claude Shannon-inspired information theory, Alan Turing-inspired pattern formation, and molecular microbiology. He later joined the faculty at Massachusetts Institute of Technology and became a founding member of centers affiliated with Wyss Institute for Biologically Inspired Engineering and collaborations with investigators at Harvard Medical School and Broad Institute. His groups have published alongside researchers from Stanford University, University of California, Berkeley, Princeton University, and Johns Hopkins University on synthetic gene circuits, stochastic gene expression, and systems-level antibiotic responses.
Collins is credited with seminal contributions to engineered genetic circuits such as synthetic toggle switches and oscillators inspired by earlier theoretical work from Michael Elowitz and Stanley N. Cohen. His laboratory characterized mechanisms of antibiotic tolerance and persistence in bacteria, advancing hypotheses related to toxin–antitoxin modules previously studied by teams at University of Cambridge and University of Oxford. He introduced innovative approaches to kill-switch design and programmable cell death building on concepts from George Church and Drew Endy. Collins' teams developed paper-based diagnostics and toehold-switch riboregulators leveraging methods from James A. Thomson-adjacent efforts in RNA engineering and collaborations with groups at MIT Media Lab and Wyss Institute. His interdisciplinary work connects to advances in microfluidics from Stephen Quake and single-cell sequencing methods emerging from Illumina-associated research.
Collins cofounded and advised biotechnology companies translating synthetic biology into products, engaging with startups in diagnostics, antimicrobials, and engineered probiotics. His commercial endeavors include ventures working with partners at McKinsey & Company-backed incubators, collaborations with Novartis, Pfizer, and partnerships with Bill & Melinda Gates Foundation-funded initiatives. Startups originating from his lab pursued technologies related to paper-based sensors, living therapeutics for gastrointestinal disorders, and rapid pathogen detection used in field settings alongside organizations like World Health Organization and Centers for Disease Control and Prevention.
Collins has received recognition from institutions including the National Academy of Engineering, the National Academy of Sciences, and fellowships from organizations such as the John D. and Catherine T. MacArthur Foundation and Darwin Trust. He has been honored with prizes and awards associated with American Academy of Arts and Sciences, Ellison Medical Foundation, and professional societies including the American Society for Microbiology and Biophysical Society for contributions to synthetic biology and antibiotic research.
Collins' legacy includes training a generation of scientists who have taken faculty positions at institutions like Yale University, University of California, San Diego, ETH Zurich, and entrepreneurial roles across the biotechnology industry. His translational focus influenced public health responses to infectious disease threats and informed policy dialogues involving National Institutes of Health and Defense Advanced Research Projects Agency. Outside the laboratory he has participated in advisory roles for nonprofit groups and educational outreach efforts connected to Khan Academy-style initiatives and museum exhibits at institutions such as the Museum of Science (Boston).
Category:American biologists Category:Synthetic biologists Category:Massachusetts Institute of Technology faculty